INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann

Name: A1-R101||A2-R101||INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann | Boehringer Ingelheim
Keywords: Our mission is to advance treatments for the most difficult-to-treat inflammatory and fibrotic diseases of the lungs, gut, skin, and joints.

19/02/2024 | Author: Boehringer Ingelheim

Document ID: EM-MY-100279